{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:45:16Z","timestamp":1785908716527,"version":"3.56.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the therapeutic management of patients with active adult-onset Still\u2019s disease (AOSD) in a multicentre real-world setting and to provide and compare current real-world treatment strategies with existing recent international recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      From January 2022 to December 2023, 173 consecutive patients with active AOSD attending centres participating in the\n                      <jats:italic>Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale<\/jats:italic>\n                      (GIRRCS) AOSD research study group were prospectively enrolled. Demographic, clinical, and laboratory data were collected, and therapeutic strategies prescribed by the treating physicians were systematically recorded. Factors associated with the administration of biologic disease-modifying antirheumatic drugs (bDMARDs), including IL-1 and IL-6 inhibitors, were analysed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Glucocorticoids were administered in 97.7% of patients. Conventional synthetic DMARDs were prescribed in 58.8% of cases, mainly methotrexate and cyclosporin A. Overall, 43.3% of patients received bDMARDs, predominantly IL-1 and IL-6 inhibitors. Specifically, 33.5% were treated with IL-1 inhibitors, 5.8% with IL-6 inhibitors, and 4.0% with tumour necrosis factor inhibitors. After three months of treatment, 86.7% of patients achieved clinical inactive disease as assessed by the treating physician. Comparing recorded treatment strategies with international recommendations, no compliance was found regarding the use of glucocorticoids, which are recommended to be markedly limited or avoided, and early administration of bDMARDs, which were administered within 3 months in a minority of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This multicentre real-world study outlines current therapeutic approaches for patients with active AOSD and highlights a gap between international treatment recommendations and clinical practice, underscoring the need for further studies to optimize patient management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1852661","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:54:55Z","timestamp":1785905695000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world therapeutic strategies in active adult-onset Still\u2019s disease: clinical insights from the GIRRCS-AOSD study group"],"prefix":"10.3389","volume":"17","author":[{"given":"Piero","family":"Ruscitti","sequence":"first","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L\u2019Aquila","place":["L\u2019Aquila, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Iacono","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, University of Campania \u201cLuigi Vanvitelli\u201d","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Riccio","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, University of Campania \u201cLuigi Vanvitelli\u201d","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariachiara","family":"Visconti","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, University of Campania \u201cLuigi Vanvitelli\u201d","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vitale","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena and Azienda Ospedaliero-Universitaria Senese [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory, and Autoimmune Diseases (RITA) Center]","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Caggiano","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena and Azienda Ospedaliero-Universitaria Senese [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory, and Autoimmune Diseases (RITA) Center]","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Sbalchiero","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena and Azienda Ospedaliero-Universitaria Senese [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory, and Autoimmune Diseases (RITA) Center]","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovico","family":"De Stefano","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Therapeutics, University of Pavia","place":["Pavia, Italy"]},{"name":"Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clelia","family":"Zampaglione","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Therapeutics, University of Pavia","place":["Pavia, Italy"]},{"name":"Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"La Barbera","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Rheumatology Section-\u201dP. Giaccone\u201d, University of Palermo","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Navarini","sequence":"additional","affiliation":[{"name":"Clinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Campus Bio-Medico, Via \u00c1lvaro del Portillo","place":["Rome, Italy"]},{"name":"Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome \"Campus Biomedico\"","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Atzeni","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina","place":["Messina, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ursini","sequence":"additional","affiliation":[{"name":"Medicine and Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli","place":["Bologna, Italy"]},{"name":"Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum University of Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Caso","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Costa","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Prete","sequence":"additional","affiliation":[{"name":"Internal Medicine Unit, Department of InterdisciplinaryMedicine, University of Bari Medical School","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Perosa","sequence":"additional","affiliation":[{"name":"Rheumatic and Systemic Autoimmune Diseases Unit, Department of Interdisciplinary Medicine (DIM), University of Bari Medical School","place":["Bari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Guggino","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Rheumatology Section-\u201dP. Giaccone\u201d, University of Palermo","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Bugatti","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Therapeutics, University of Pavia","place":["Pavia, Italy"]},{"name":"Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlomaurizio","family":"Montecucco","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Therapeutics, University of Pavia","place":["Pavia, Italy"]},{"name":"Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo","place":["Pavia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Fabiani","sequence":"additional","affiliation":[{"name":"Ophthalmology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena and Azienda Ospedaliero-Universitaria Senese [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory, and Autoimmune Diseases (RITA) Center]","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cipriani","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L\u2019Aquila","place":["L\u2019Aquila, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ciccia","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, University of Campania \u201cLuigi Vanvitelli\u201d","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giacomelli","sequence":"additional","affiliation":[{"name":"Clinical and Research Section of Rheumatology and Clinical Immunology, Fondazione Policlinico Campus Bio-Medico, Via \u00c1lvaro del Portillo","place":["Rome, Italy"]},{"name":"Rheumatology and Clinical Immunology, Department of Medicine, School of Medicine, University of Rome \"Campus Biomedico\"","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01065-6","article-title":"Recent advances and evolving concepts in still's disease","volume":"20","author":"Ruscitti","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jaut.2018.07.018","article-title":"A comprehensive review on adult onset still's disease","volume":"93","author":"Giacomelli","year":"2018","journal-title":"J Autoimmun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0081-x","article-title":"Mechanisms, biomarkers and targets for adult-onset still's disease","volume":"14","author":"Feist","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003419","article-title":"Derivation and validation of four patient clusters in still's disease, results from GIRRCS AOSD-study group and AIDA network still disease registry","volume":"9","author":"Ruscitti","year":"2023","journal-title":"RMD Open"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/art.42845","article-title":"The systemic score may identify life-threatening evolution in still disease: data from the GIRRCS AOSD-study group and the AIDA network still disease registry","volume":"76","author":"Ruscitti","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2022.2126764","article-title":"Perspectives on the use of non-biological pharmacotherapy for adult-onset still's disease","volume":"23","author":"Di Cola","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"B7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/14712598.2024.2307340","article-title":"The latest advances in the use of biological DMARDs to treat still's disease","volume":"24","author":"Di Cola","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2023-0995","article-title":"Systematic review and metaanalysis of pharmacological interventions in adult-onset still disease and the role of biologic disease-modifying antirheumatic drugs","volume":"51","author":"Ruscitti","year":"2024","journal-title":"J Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead461","article-title":"Management of adult-onset still's disease: evidence- and consensus-based recommendations by experts","volume":"63","author":"Leavis","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225851","article-title":"EULAR\/PReS recommendations for the diagnosis and management of still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset still's disease","volume":"83","author":"Fautrel","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B11","article-title":"Preliminary criteria for classification of adult still's disease","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"J Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(25)00377-7","article-title":"Development and validation of clinical criteria for the definition of disease activity in adult-onset still's disease: a cohort study","volume":"8","author":"Ruscitti","year":"2026","journal-title":"Lancet Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ero.2025.05.001","article-title":"Clinical, biological, and radiological changes under therapy, and criteria of clinical response as well as remission in adult onset still\u2019s disease: a systematic literature review \u2013 EULAR rheumatology open","author":"Girard-Guyonvarc\u2019h","year":"2025","journal-title":"EULAR Rheumatol Open"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ero.2025.05.004","article-title":"Items identified by expert physicians for a disease activity score for adult-onset still\u2019s disease (the DAVID score): results of a web-based delphi study \u2013 EULAR rheumatology open","author":"Mitrovic","year":"2025","journal-title":"EULAR Rheumatol Open"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ero.2025.11.015","article-title":"The EULAR points to consider regarding the development of criteria for the assessment of the disease activity in adult-onset still\u2019s disease \u2013 EULAR rheumatology open","author":"Ruscitti","year":"2025","journal-title":"EULAR Rheumatol Open"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015123","article-title":"Managing adult-onset still's disease: the effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study","volume":"98","author":"Ruscitti","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12916-016-0738-8","article-title":"Adult-onset still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers","volume":"14","author":"Ruscitti","year":"2016","journal-title":"BMC Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0235326","article-title":"Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset still's disease. Analysis of the multicentre gruppo italiano di ricerca in reumatologia clinica e sperimentale (GIRRCS) cohort","volume":"15","author":"Di Benedetto","year":"2020","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152244","article-title":"The administration of methotrexate in patients with still's disease, \"real-life\" findings from AIDA network still disease registry","volume":"62","author":"Ruscitti","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2014.962996","article-title":"Methotrexate: an old new drug in autoimmune disease","volume":"10","author":"Cipriani","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00225-X","article-title":"Advancing personalised precision treatment for still's disease based on molecular characteristics and disease progression","volume":"7","author":"Shen","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103400","article-title":"Expert consensus on the treatment of patients with adult-onset still's disease with the goal of achieving an early and long-term remission","volume":"22","author":"Giacomelli","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.06.004","article-title":"Adult-onset still's disease in focus: clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies","volume":"51","author":"Efthimiou","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/art.40501","article-title":"Editorial: toward personalized treatment for systemic juvenile idiopathic arthritis","volume":"70","author":"Vastert","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/art.38615","article-title":"Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis","volume":"66","author":"Nigrovic","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103114","article-title":"Expanding the spectrum of the hyperferritinemic syndrome, from pathogenic mechanisms to clinical observations, and therapeutic implications","volume":"21","author":"Ruscitti","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152089","article-title":"Efficacy and safety of tocilizumab in adult-onset still's disease: real-life experience from the international AIDA registry","volume":"57","author":"Sota","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1590334","article-title":"Tocilizumab for the treatment of adult-onset still's disease","volume":"19","author":"Casta\u00f1eda","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.04.004","article-title":"Racial\/ethnic variations in morbidity and mortality in adult onset still's disease: an analysis of national dataset","volume":"49","author":"Mehta","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152264","article-title":"Burden of adult-onset still's disease: a systematic review of health-related quality of life, utilities, costs and resource use","volume":"63","author":"Ruscitti","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"B31","first-page":"72","volume-title":"Budget impact analysis of anakinra in the treatment of patients with Still's disease","author":"Ravasio","year":"2020"},{"key":"B32","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/annrheumdis-2012-202603","article-title":"Inequities in access to biologic and synthetic DMARDs across 46 European countries","volume":"73","author":"Putrik","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213289","article-title":"Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry","volume":"77","author":"Bergstra","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2025.105311","article-title":"Disparities in the organisation of national healthcare systems for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe","volume":"156","author":"Michelsen","year":"2025","journal-title":"Health Policy"},{"key":"B35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ccc.2021.07.002","article-title":"Decision making: healthy heuristics and betraying biases","volume":"38","author":"Mangus","year":"2022","journal-title":"Crit Care Clin"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac712","article-title":"Diagnostic and therapeutic algorithms for monogenic autoinflammatory diseases presenting with recurrent fevers among adults","volume":"62","author":"Delplanque","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2111003","article-title":"Fever of unknown origin","volume":"386","author":"Haidar","year":"2022","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215048","article-title":"Classification criteria for autoinflammatory recurrent fevers","volume":"78","author":"Gattorno","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-017-1622-z","article-title":"The diagnostic evaluation of patients with a suspected hereditary periodic fever syndrome: experience from a referral center in Italy","volume":"12","author":"Vitale","year":"2017","journal-title":"Intern Emerg Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3293145","article-title":"Hints for genetic and clinical differentiation of adult-onset monogenic autoinflammatory diseases","volume":"2019","author":"Gaggiano","year":"2019","journal-title":"Mediators Inflammation"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/art.43052","article-title":"Macrophage activation syndrome","volume":"77","author":"Nigrovic","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103880","article-title":"Managing the clinical heterogeneity of patients with still's disease, from early diagnosis to timely treatment","volume":"24","author":"Ruscitti","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.04.016","article-title":"Pulmonary arterial hypertension in adults with still's disease: another pulmonary manifestation associated with HLA-DRB1*15","volume":"84","author":"Boucly","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf021","article-title":"The clinical assessment of lung involvement in patients with still's disease, results from the multicentre international AIDA network still's disease registry","volume":"64","author":"Ruscitti","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2024-0683","article-title":"Evaluation of myocarditis in patients with still disease: clinical findings from the multicenter international AIDA network still disease registry","volume":"52","author":"Ruscitti","year":"2025","journal-title":"J Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1852661\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:55:03Z","timestamp":1785905703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1852661\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2026.1852661"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1852661","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"article-number":"1852661"}}